CTDSP1: A Potential Drug Target and Biomarker (G58190)

Target Name: CTDSP1

NCBI ID: G58190

CTDSP1

CTDSP1: A Potential Drug Target and Biomarker

Introduction

CTDSP1 (Cadherin-Tendon-Sarcoma-Specific Protein 1) is a protein that is expressed in various tissues, including muscle, tendon, and sarcoma. It is a member of the cadherin family, which is a transmembrane protein that plays a critical role in cell-cell adhesion. The identification of potential drug targets and biomarkers for sarcoma has been a major focus of research in recent years, and CTDSP1 is one of the most promising candidates.

Disegno

The goal of this article is to provide an overview of CTDSP1, including its structure, function, and potential as a drug target and biomarker.

Structure and Function

CTDSP1 is a 21-kDa protein that is expressed in muscle, tendon, and various sarcoma tissues. It consists of 195 amino acid residues and has a calculated pI of 2.8. CTDSP1 is predominantly localized to the cytoplasm and is also found in the endoplasmic reticulum (ER) and the plasma membrane (PM). It has been shown to interact with various cell surface molecules, including cadherins, integrins, and vimentin.

CTDSP1 functions as a negative regulator of cell adhesion, and its activity has been implicated in the development and progression of various cancers, including sarcoma. It has been shown to promote the formation of tight junctions, which are essential for maintaining tissue structure and function. In addition, CTDSP1 has been shown to inhibit the assembly and disassembly of adhesion molecules, including cadherins, which are critical for cell-cell adhesion.

Potential as a Drug Target

The potential of CTDSP1 as a drug target is based on its role as a negative regulator of cell adhesion and its involvement in the development and progression of various cancers. CTDSP1 has been shown to interact with various cell surface molecules, including cadherins, integrins, and vimentin. This suggests that it may be a potential target for drugs that are designed to inhibit cell adhesion or disrupt the formation of tight junctions.

In addition, the role of CTDSP1 in the regulation of cell adhesion has been implicated in the development of various types of cancer, including sarcoma. Therefore, targeting CTDSP1 with drugs that are designed to inhibit its activity may be a promising strategy for the treatment of Sarcoma.

Potential as a Biomarker

The potential of CTDSP1 as a biomarker for sarcoma is based on its expression and its ability to interact with various cell surface molecules. CTDSP1 has been shown to be expressed in various sarcoma tissues and has been used as a biomarker for the diagnosis and prognosis of sarcoma.

In addition, the regulation of cell adhesion by CTDSP1 has been implicated in the development and progression of various cancers, including sarcoma. Therefore, the activity of CTDSP1 may be an attractive biomarker for the detection and prognosis of sarcoma.

Conclusion

CTDSP1 is a protein that is expressed in various tissues and has been shown to play a critical role in the regulation of cell adhesion. Its potential as a drug target and biomarker for sarcoma makes it an attractive target for further research. Further studies are needed to fully understand the role of CTDSP1 in the development and progression of sarcoma, as well as its potential as a drug and biomarker.

Protein Name: CTD Small Phosphatase 1

Functions: Preferentially catalyzes the dephosphorylation of 'Ser-5' within the tandem 7 residue repeats in the C-terminal domain (CTD) of the largest RNA polymerase II subunit POLR2A. Negatively regulates RNA polymerase II transcription, possibly by controlling the transition from initiation/capping to processive transcript elongation. Recruited by REST to neuronal genes that contain RE-1 elements, leading to neuronal gene silencing in non-neuronal cells

The "CTDSP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTDSP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets